aTyr starts Phase 2 for interstitial lung disease therapy

aTyr Pharma Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT™ study. The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company’s lead therapeutic candidate, efzofitimod, compared to placebo in patients with systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease (ILD).

Efzofitimod is a first-in-class biologic immunomodulator that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. Efzofitimod has been granted U.S. Food and Drug Administration (FDA) and European Union orphan drug and U.S. FDA Fast Track designations for SSc.

https://www.biospace.com/article/releases/atyr-pharma-announces-dosing-of-first-patient-in-phase-2-efzo-connect-study-of-efzofitimod-in-patients-with-ssc-ildmultiple-centers-in-the-u-s-are-open-for-enrollment/